Corvus Pharmaceuticals regains Nasdaq minimum bid price compliance

Corvus Pharmaceuticals, Inc.

Received Nasdaq deficiency notice on Oct 25, 2022 for bid price below $1.00.
Compliance period was 180 days, expiring April 24, 2023.
On April 21, 2023, Nasdaq confirmed compliance after 10 consecutive business days of closing bid price at or above $1.00 from April 6-20.
Matter is now closed; no further action needed on listing requirement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.